GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
GYRE THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.09+0.01 (+0.16%)
Close on Oct 19, 2026
- Market cap
- $612.88M
- P/E (TTM)
- –
- Dividend yield
- –
GYRE THERAPEUTICS, INC. revenue by segment
By business segment
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 22 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gyre Pharmaceuticals | – | $13.19M | $19.99M | $19.07M | $16.26M | $16.37M | $22.02M | $19.29M | $26.00M | $27.16M | $24.46M | – | – |
| Other Unallocated Amount | – | -$22.00K | -$19.00K | -$12.00K | -$6.00K | -$5.00K | -$2.00K | – | – | – | -$3.29M | – | – |
| Gyre | – | -$13.31M | -$8.49M | -$7.03M | -$6.91M | -$6.00M | -$5.86M | – | – | – | – | – | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration | – | – | – | – | – | – | – | – | – | – | – | $794.00K | – | – |
| ETUARY | – | – | – | $107.36M | $102.26M | $100.66M | $105.76M | $105.05M | $111.55M | $115.65M | $113.45M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Gyre Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.